Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (DME)
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study is intended to assess the safety, tolerability and evidence of pharmacodynamic
activity of a single intravitreal (IVT) injection of UBX1325 in patients with diabetic
macular edema (DME)